Under the terms of the multi-year agreement, “Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario, for distribution worldwide.”
National Resilience was founded relatively recently, in November 2020, and describes itself as “a manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.”
It has since been building “a sustainable network of high-tech, end-to-end manufacturing solutions with the aim to ensure the medicines of today and tomorrow can be made quickly, safely and at scale.”
It further plans to “reinvent biomanufacturing” and “democratize access to medicines,” namely gene therapies, experimental vaccines and other “medicines of tomorrow.”
In pursuit of those goals, the company announced it would “actively invest in developing powerful new technologies to manufacture complex medicines that are defining the future of therapeutics, including cell and gene therapies, viral vectors, vaccines and proteins.”
The company initially marketed its manufacturing capabilities as “the Resilience platform,” and offers principally “RNA Modalities,” including RNA development for vaccines, gene editing and therapeutics; and “Virus Production,” including viral vectors, oncolytic viruses (i.e. a virus engineered to preferentially attack cancer cells), viruses for use in vaccine development and gene-edited viruses for unspecified purposes.
It is worth noting that, to date, many controversial “gain-of-function” experiments have justified modifying viruses for the same purposes as described by National Resilience’s Virus Production capabilities.
In addition, National Resilience offers product formulations and other modalities, such as biologics and cell therapies, to its clientele and the “Virus Production” of its website has since been removed.